Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
Finlay Minerals Appoints an Executive Chairman, President & CEO, and Vice President, Corporate Development
